OCEL实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (5 Mar 2024 @ 04:14):

Organicell Regenerative Medicine, Inc., a clinical-stage biopharmaceutical company, focuses on the development of biological therapeutics for the treatment of degenerative diseases...

Stats
今日成交量	4 735.00
平均成交量	4 716.00
市值	19.97M
EPS	$-0.00114 ( 2023-07-30 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.567
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2023-06-29	Leider Harry L.	Buy	500 000	Common Stock
2023-06-28	Leider Harry L.	Buy	549 450	Common Stock
2023-12-19	Leider Harry L.	Sell	5 248	Common Stock
2023-07-07	Skycrest Holdings, Llc	Buy	320 710	Common Stock
2023-06-29	Skycrest Holdings, Llc	Buy	200 000	Common Stock

INSIDER POWER
-77.73
Last 93 transactions
Buy: 116 969 610 \| Sell: 385 387 546

Organicell Regenerative 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Organicell Regenerative 财务报表

Annual	2023
营收:	$4.56M
毛利润:	$4.05M (88.86 %)
EPS:	$-0.990

FY	2023
营收:	$4.56M
毛利润:	$4.05M (88.86 %)
EPS:	$-0.990

FY	2022
营收:	$6.49M
毛利润:	$5.74M (88.39 %)
EPS:	$-1.570

FY	2021
营收:	$5.60M
毛利润:	$5.05M (90.21 %)
EPS:	$-0.0100

Financial Reports:

No articles found.

Organicell Regenerative

Organicell Regenerative Medicine, Inc., a clinical-stage biopharmaceutical company, focuses on the development of biological therapeutics for the treatment of degenerative diseases. Its leading product candidate is Zofin, an acellular, biologic therapeutic derived from perinatal sources and is manufactured to retain naturally occurring microRNAs without the addition or combination of any other substance or diluent, which is in Phase I/II clinical trial to treat COVID-19. The company also provides independent education, advertising, and marketing services to medical and other healthcare, anti-aging, and regenerative service providers. It has a research and development agreement with the Centers for Disease Control and Prevention to determine the anti-inflammatory and anti-infective effectiveness of Zofin in experimental models of influenza infection; and an agreement with Oklahoma State University to evaluate Zofin for the treatment of respiratory diseases caused by virus infections of pandemic potential. The company was formerly known as Biotech Products Services and Research, Inc. and changed its name to Organicell Regenerative Medicine, Inc. in June 2018. Organicell Regenerative Medicine, Inc. was incorporated in 2011 and is headquartered in Miami, Florida.